Long-Term Safety from the Raltegravir Clinical Development Program

Eitemau Tebyg

• Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
  gan: Lennox, Jeffrey L., et al.
  Cyhoeddwyd: (2010)
• Association between First-Year Virologic Response to Raltegravir and Long-Term Outcomes in Treatment-Experienced Patients with HIV-1 Infection
  gan: Eron, Joseph J., et al.
  Cyhoeddwyd: (2014)
• Long-Term Efficacy and Safety of the HIV Integrase Inhibitor Raltegravir in Patients With Limited Treatment Options in a Phase II Study
  gan: Gatell, Jose M., et al.
  Cyhoeddwyd: (2010)
• Long-term efficacy and safety of raltegravir in the management of HIV infection
  gan: Liedtke, Michelle D, et al.
  Cyhoeddwyd: (2014)
• Long-Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment-Experienced Patients with Drug-Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials
  gan: Steigbigel, Roy T., et al.
  Cyhoeddwyd: (2010)